MedCity News September 23, 2024
Ron Kraus

The biopharmaceutical industry clearly isn’t going anywhere, but we’ve been in a downward business cycle. We’ve learned a lot from the pandemic and have adopted novel approaches to development and this current economic challenge will also inform us. In the meantime, adopting these strategies can de-risk your development programs.

Imagine a world without the life-saving drugs and treatments that have become integral to modern medicine. Our quality of life would suffer, average life expectancy would decline, technological advancements in healthcare would stall, and the global burden of disease would be overwhelming. The biopharma industry, which discovers, develops, produces, and markets essential medications, has not only revolutionized healthcare but has driven economic growth by creating highly skilled, well-paying jobs.

However, the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More
Pharma Pulse 11/25/24: Deepening Patient Relationships,
Halozyme abandons its €2bn pursuit of Evotec
BridgeBio poised to challenge Pfizer after Attruby approval
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy

Share This Article